Cyclobenzaprine extended release - Adare Pharmaceuticals

Drug Profile

Cyclobenzaprine extended release - Adare Pharmaceuticals

Alternative Names: Amrix; Bonelax; Bonelax ER; Cyclobenzaprine hydrochloride extended-release capsules; EUR-1002

Latest Information Update: 10 Apr 2015

Price : $50

At a glance

  • Originator Eurand
  • Developer Adare Pharmaceuticals; Teva Pharmaceutical Industries
  • Class Dibenzocycloheptenes; Muscle relaxants; Small molecules
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Musculoskeletal pain; Spasm

Highest Development Phases

  • Marketed Musculoskeletal pain; Spasm
  • No development reported Migraine

Most Recent Events

  • 02 Apr 2015 Aptalis Pharmaceuticals has been acquired by TGP and renamed Adare Pharmaceuticals
  • 16 Mar 2015 Cyclobenzaprine extended release - Aptalis is available for licensing in Asia as of 16 Mar 2015. http://www.aptalispharmaceuticaltechnologies.com
  • 16 Mar 2015 No development reported - Phase-III for Migraine in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top